Average Cost per Person Vaccinated and per Death Averted for Scaling Up Immunization Coverage and Adding in Selected New Vaccines in a Hypothetical Population of 1 million for 2002-11 (2001 US$, current vaccine prices) | East Asia and the Pacific | Europe and Central Asia | Latin America and the Caribbean | Middle East and North Africa | South Asia | Sub-Saharan Africa |
| Traditional EPI (mix of strategies) |
| Incremental discounted cost/person vaccinated | 12.03 | 11.54 | 10.89 | 12.84 | 11.58 | 11.16 |
| Incremental discounted deaths averted | 3,165 | 747 | 2,552 | 4,576 | 7,584 | 14,584 |
| Incremental discounted cost/death averted | 478 | 1,754 | 791 | 698 | 274 | 169 |
| Tetanus toxoid (mix of strategies) |
| Incremental discounted cost/person vaccinated | 4.06 | 3.34 | 3.28 | 3.34 | 3.98 | 3.88 |
| Incremental discounted deaths averted | 343 | 2 | 200 | 465 | 2,815 | 2,412 |
| Incremental discounted cost/death averted | 1,541 | >190,000 | 3,117 | 1,880 | 271 | 394 |
| Second opportunity for measles (fixed facility) |
| Incremental discounted cost/person vaccinated | 1.08 | 1.05 | 0.98 | 1.19 | 1.04 | 1.00 |
| Incremental discounted deaths averted | 1,138 | 599 | 95 | 1,304 | 2,509 | 9,646 |
| Incremental discounted cost/death averted | 119 | 199 | 1,906 | 228 | 74 | 23 |
| Pentavalent vaccine-DTP-HepB-Hib- (mix of strategies) |
| Incremental discounted cost/person vaccinated | 15.14 | 14.61 | 15.69 | 16.23 | 15.24 | 11.68 |
| Incremental discounted deaths averted | 139 | 39 | 129 | 318 | 248 | 1,952 |
| Incremental discounted cost/death averted | 13,697 | 42,529 | 22,540 | 12,564 | 10,950 | 1,319 |
| Yellow fever (campaigns) |
| Incremental discounted cost/person vaccinated | n.a. | n.a. | 1.43 | n.a. | n.a. | 1.42 |
| Incremental discounted deaths averted | n.a. | n.a. | 94 | n.a. | n.a. | 376 |
| Incremental discounted cost/death averted | n.a. | n.a. | 2,810 | n.a. | n.a. | 834 |
| Incremental discounted cost/person vaccinated (mix of strategies) |
| Hepatitis B monovalent (birth dose) | 2.26 | 2.15 | 2.36 | 2.37 | 2.24 | 2.02 |
| DTP-hepatitis B (tetravalent) | 7.85 | 7.57 | 7.34 | 8.03 | 7.55 | 7.26 |
| Rubella (campaigns) | 1.20 | 1.19 | 1.20 | 1.07 | 1.19 | 1.19 |
| Meningococcal A (fixed facilities) | n.a. | n.a. | n.a. | 2.73 | n.a. | 2.33 |
| Japanese encephalitis (fixed facilities) | 4.56 | n.a. | n.a. | n.a. | 4.37 | n.a. |
| Injectable polio vaccine (monovalent) | 7.12 | 6.72 | 6.42 | 7.32 | 6.85 | 6.60 |
| Injectable polio vaccine (combination with DTP) | 13.88 | 14.84 | 14.62 | 15.28 | 14.77 | 14.19 |
Source: Authors' calculations.
Note: n.a. refers to not applicable when a specific disease is not prevalent in a specific region.
